Andra Ababei-Bobu

Mrs. Andra Ababei-Bobu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in Polymers
Verified
Journal Article
Open access
PDF file
Andreea Teodora IacobAndreea Teodora Iacob
Andreea Teodora Iacob
AAAndra Ababei-Bobu
Andra Ababei-Bobu
Oana-Maria CHIRLIUOana-Maria CHIRLIU
Oana-Maria CHIRLIU
Florentina Geanina LupascuFlorentina Geanina Lupascu
Florentina Geanina Lupascu
IVIoana-Mirela Vasincu
Ioana-Mirela Vasincu
LPLenuta Profire
Lenuta Profire
The development of nanocarriers for drug delivery has drawn a lot of attention due to the possibility for tailored delivery to the ill region while preserving the neighboring healthy tissue. In medicine, delivering drugs safely and effectively has never been easy; therefore, the creation of surfactant-based vesicles (niosomes) to enhance medication delivery has gained attention in the past years. Niosomes (NIOs) are versatile drug delivery systems that facilitate applications varying from transdermal transport to targeted brain delivery. These self-assembling vesicular nano-carriers are formed by hydrating cholesterol, non-ionic surfactants, and other amphiphilic substances. The focus of the review is to report on the latest NIO-type formulations which also include biopolymers from the polysaccharide class, highlighting their role in the development of these drug delivery systems (DDSs). The NIO and polysaccharide types, together with the recent pharmaceutical applications such as ocular, oral, nose-to brain, pulmonary, cardiac, and transdermal drug delivery, are all thoroughly summarized in this review, which offers a comprehensive compendium of polysaccharide-based niosomal research to date. Lastly, this delivery system’s limits and prospects are also examined.

14 November 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AAAndra Ababei-Bobu
Andra Ababei-Bobu
BPBianca Stefania Profire
Bianca Stefania Profire
Andreea Teodora IacobAndreea Teodora Iacob
Andreea Teodora Iacob
Oana-Maria CHIRLIUOana-Maria CHIRLIU
Oana-Maria CHIRLIU
Florentina Geanina LupascuFlorentina Geanina Lupascu
Florentina Geanina Lupascu
LPLenuta Profire
Lenuta Profire
Niosomes (NIOs), a class of nanovesicular drug delivery system, have garnered significant attention due to their unique architecture, resulting from the self-assembly of non-ionic surfactants (with or without cholesterol) in aqueous media. This bilayered structure enables the encapsulation of both hydrophilic agents in the aqueous core and lipophilic compounds within the lipid bilayer, offering remarkable versatility in therapeutic applications. This article provides an overview of the key principles underlying niosomal formulations, including their composition, preparation methods, formulation conditions and the critical physicochemical parameters influencing vesicle formation and performance. Special emphasis is placed on recent innovations in surface and content modifications that have led to the development of stimuli-responsive niosomal systems, with precise and controlled drug release. These smart carriers are designed to respond to endogenous stimuli (such as pH variations, redox gradients, enzymatic activity, or local temperature changes in pathological sites), as well as to exogenous triggers (including light, ultrasound, magnetic or electric fields, and externally applied hyperthermia), thereby enhancing therapeutic precision. These surface and content modulation strategies effectively transform conventional NIOs into intelligent, stimuli-responsive platforms, reinforcing their innovative role in drug delivery and highlighting their significant potential in the development of smart nanomedicine.

12 February 2026 in Polymers
Verified
Journal Article
Open access
PDF file
AAAndra Ababei-Bobu
Andra Ababei-Bobu
ASAlexandru SAVA
Alexandru SAVA
Florentina Geanina LupascuFlorentina Geanina Lupascu
Florentina Geanina Lupascu
Oana-Maria CHIRLIUOana-Maria CHIRLIU
Oana-Maria CHIRLIU
BPBianca Stefania Profire
Bianca Stefania Profire
LPLenuta Profire
Lenuta Profire
Glibenclamide (Gli), widely used in the management of type 2 diabetes mellitus (T2DM), shows low oral bioavailability, while curcumin (Cur) is limited by poor aqueous solubility and instability. This study reports the development of a niosomal co-delivery system combining hypoglycemic and antioxidant agents to improve formulation performance for T2DM. Gli and Cur were co-encapsulated into niosomal vesicles (NIOs) using the thin-film hydration method, followed by surface coating with chitosan (CS). The formulations were characterized by dynamic light scattering, scanning transmission electron microscopy, X-ray diffraction, and Fourier-transform infrared spectroscopy, complemented by in vitro release studies under simulated gastrointestinal conditions. The prepared NIOs exhibited particle sizes between 413.5 and 576.9 nm, with encapsulation efficiency strongly dependent on formulation composition. The optimized system showed high encapsulation efficiency for both Gli (98.95 ± 0.87%) and Cur (91.09 ± 2.00%). In vitro release studies demonstrated enhanced release compared with the physical mixture, providing gastric protection and sustained intestinal delivery. Release kinetics indicated controlled drug release governed by diffusion- and erosion-based mechanisms. Both uncoated and CS-coated NIOs displayed good physical and osmotic stability, with CS coating further reducing drug leakage. These results highlight the potential of niosomal systems for efficient Gli and Cur administration in T2DM.